February 2, 2024 07:30 AM EST

Novartis ends license agreement for cancer drug with Allarity Therapeutics for lack of payment

Katherine Lewin

News Reporter

Allarity Therapeutics’ 2018 license agreement with Novartis for the cancer drug dovitinib has come to an end due to lack of payment, the Boston biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis ends license agreement for cancer drug with Allarity Therapeutics for lack of payment

Katherine Lewin

News Reporter

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers

No­var­tis ends li­cense agree­ment for can­cer drug with Al­lar­i­ty Ther­a­peu­tics for lack of pay­ment

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Novartis ends license agreement for cancer drug with Allarity Therapeutics for lack of payment

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers